Boehringer Ingelheim’s SCOVELLA receives positive CVMP opinion

Key highlights
  • The CVMP recommended EU marketing authorization for velagliflozin oral solution, SCOVELLA.
  • The proposed indication is to reduce hyperinsulinaemia and associated laminitis risk in horses with Equine Metabolic Syndrome that do not respond to changes in husbandry and exercise.
  • If authorized by the European Commission, SCOVELLA would be the EU’s first SGLT-2 inhibitor approved for horses.
  • Insulin dysregulation is estimated to affect one in five horses and to be associated with more than 90% of laminitis cases.

Regulatory progress

The European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion recommending marketing authorization in the EU for Boehringer Ingelheim’s SCOVELLA® (velagliflozin oral solution). The European Commission must still grant authorization. The proposed indication is to reduce hyperinsulinaemia and the associated risk of laminitis in horses with Equine Metabolic Syndrome that do not respond to changes in husbandry and exercise.

Product and condition

SCOVELLA is an oral SGLT-2 inhibitor designed to inhibit glucose reabsorption in the kidneys, leading to a reduction in insulin. If authorized, it would be the first SGLT-2 inhibitor approved for horses in the EU. The product was approved and introduced in Great Britain earlier this year.

Equine Metabolic Syndrome includes insulin dysregulation, which is associated with increased laminitis risk. Laminitis is a painful hoof condition; the article estimates that one-third of affected horses are euthanized within a year of diagnosis. Insulin dysregulation is estimated to affect one in five horses and to be associated with more than 90% of laminitis cases.

Source: Boehringer Ingelheim

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

1 October 2026
Boehringer Ingelheim reports Phase III survodutide results in obesity and type 2 diabetes

At 76 weeks, weight loss reached 13.1%, HbA1c fell by up to 1.21%, and gastrointestinal events led 18% of treated participants to discontinue.